Basilea Pharmaceutica AG
BPMUF
$54.00
$1.172.22%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 221.94M | 192.11M | 161.32M | 165.58M | 167.17M |
| Total Other Revenue | 15.63M | 11.23M | 6.74M | 7.52M | 8.17M |
| Total Revenue | 237.56M | 203.33M | 168.05M | 173.10M | 175.35M |
| Cost of Revenue | 131.73M | 136.55M | 140.92M | 129.83M | 117.26M |
| Gross Profit | 105.83M | 66.78M | 27.13M | 43.27M | 58.09M |
| SG&A Expenses | 35.25M | 35.16M | 34.94M | 35.05M | 34.63M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 166.98M | 171.71M | 175.87M | 164.88M | 151.88M |
| Operating Income | 70.58M | 31.62M | -7.81M | 8.22M | 23.46M |
| Income Before Tax | 68.98M | 26.75M | -15.97M | -2.29M | 10.74M |
| Income Tax Expenses | -19.58M | -17.36M | -15.10M | -7.67M | 10.40K |
| Earnings from Continuing Operations | 88.56 | 44.11 | -0.86 | 5.38 | 10.73 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 88.56M | 44.11M | -861.60K | 5.38M | 10.73M |
| EBIT | 70.58M | 31.62M | -7.81M | 8.22M | 23.46M |
| EBITDA | 73.14M | 34.19M | -5.26M | 10.78M | 26.02M |
| EPS Basic | 7.32 | 3.64 | -0.08 | 0.45 | 0.90 |
| Normalized Basic EPS | 3.57 | 1.38 | -0.83 | -0.12 | 0.56 |
| EPS Diluted | 6.64 | 3.17 | -0.34 | 0.11 | 0.50 |
| Normalized Diluted EPS | 3.11 | 1.12 | -0.89 | -0.27 | 0.32 |
| Average Basic Shares Outstanding | 48.36M | 48.27M | 48.18M | 48.07M | 47.97M |
| Average Diluted Shares Outstanding | 55.42M | 53.54M | 51.65M | 51.61M | 51.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
